目的 觀察保婦康栓聯(lián)合頭孢曲松鈉、甲硝唑治療慢性盆腔炎的臨床療效。方法 選取2013年6月—2014年6月西安市第九醫(yī)院收治的慢性盆腔炎患者80例, 隨機(jī)分為對(duì)照組和治療組, 每組40例。對(duì)照組患者給予注射用頭孢曲松鈉2.0 g加入生理鹽水250 mL, 靜脈滴注, 1次/d;同時(shí)靜脈滴注甲硝唑葡萄糖注射液250 mL, 1次/d。治療組在對(duì)照組基礎(chǔ)上, 月經(jīng)結(jié)束后3 d開始睡前使用保婦康栓, 1次/d。兩組均連續(xù)治療21 d。觀察兩組的臨床療效, 同時(shí)比較兩組臨床癥狀改善情況、炎癥因子檢測(cè)水平、超聲檢查情況及復(fù)發(fā)率。結(jié)果 治療后, 對(duì)照組和治療組的總有效率分別為72.5%、92.5%, 兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后, 兩組患者的臨床癥狀及影像學(xué)檢查均較治療前明顯好轉(zhuǎn), 且治療組優(yōu)于對(duì)照組(P<0.05)。兩組患者TNF-α、IL-8、TGF-β1、IL-1β均較同組治療前顯著降低, 同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度優(yōu)于對(duì)照組, 兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。對(duì)照組和治療組的復(fù)發(fā)率分別為17.5%、2.7%, 兩組復(fù)發(fā)率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 保婦康栓聯(lián)合頭孢曲松鈉、甲硝唑治療慢性盆腔炎具有較好的臨床療效, 可減輕患者的臨床癥狀, 降低炎癥因子水平, 在臨床具有一定的推廣應(yīng)用價(jià)值。

Objective To explore the efficacy of Baofukang Suppository combined with ceftriaxone sodium and metronidazole in treatment of chronic pelvic inflammatory. Methods Patients (80 cases) with chronic pelvic inflammatory in Ninth Hospital of Xi'an from June 2013 to June 2014 were randomly divided into control and treatment groups, and each group had 40 cases. The patients in the control group were iv administered with Ceftriaxone Sodium for injection 2.0 g adding into physiological saline 250 mL, once daily. At the same time, they were iv administered with Metronidazole and Glucose Injection 250 mL, once daily. The patients in the treatment group were given Baofukang Suppository before going to sleep 3 d after menstruation on the basis of the control group, once daily. Two groups were treated for 21 d. After treatment, the efficacy was evaluated, and improvement situation of clinical symptoms, levels of inflammatory factors, ultrasound situation and recurrence rate in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 72.5% and 92.5%, respectively, and there were differences between two groups (P < 0.05). The clinical symptoms and imaging examination in two groups were improved markedly, and these situations in the treatment group were better than those in the control group (P < 0.05). TNF-α, IL-8, TGF-β1, and IL-1β in two groups were significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). The recurrence rate in the control and treatment groups were 17.5% and 2.7%, respectively, and there were differences between two groups (P < 0.05). Conclusion Baofukang Suppository combined with ceftriaxone sodium and metronidazole has good clinical efficacy in treatment of chronic pelvic inflammatory, and can reduce the clinical symptoms, while can lower inflammatory cytokines levels, which has certain application value in clinical.